Federal Supply Schedule 36F79719D0160
Award Date
6/1/19
Last Date to Order
11/30/26
Federal Agency
Veterans Integrated Service Network 12
Awardee
Catalyst Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Catalyst Pharmaceuticals, Inc. The BPA, valued at $5,500,000, is placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of July 25, 2026. The primary purpose of this BPA is to enable the procurement of the pharmaceutical product Firdapse (amifampridine), an FDA-approved...
The Department of Veterans Affairs (VA) has awarded Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies, an IDV Federal Supply Schedule contract (36F79723D0194) valued at over $16.3 million. This multiple-award contract covers the procurement of drugs, pharmaceuticals, and hematology-related products through September 2028. Under this IDV, the VA Veterans Integrated Service Network 12 has issued firm fixed-price delivery orders for Acorda's Levodopa 42mg...
The key products and services being delivered under the federal contract IDV award to Amylyx Pharmaceuticals Inc. (doing business as Amylyx) are the procurement of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS), for the U.S. Department of Veterans Affairs (VA). Amylyx, a self-certified small disadvantaged business, has secured multiple contract vehicles with the VA to facilitate the distribution of its pharmaceutical products to veterans, including a Federal Supply...
The Department of Veterans Affairs (VA) has awarded multiple firm fixed price delivery order contracts to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business, for the provision of RELYVRIO, Amylyx's pharmaceutical product containing sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis (ALS). These delivery orders, valued at over $3 million in aggregate, were placed against Amylyx's existing federal contract vehicles, including a...
The subject federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a division of the U.S. Department of Veterans Affairs (VA), to Amylyx Pharmaceuticals Inc. (Amylyx). The BPA, valued at $50,000, is for the procurement of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS) developed by Amylyx. As a self-certified small disadvantaged business, Amylyx has established several contract vehicles with the VA to facilitate the...
The U.S. Department of Veterans Affairs (VA) has awarded a $98.2 million multiple-award indefinite-delivery vehicle (IDV) contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods. The contract, with a period of performance through December 2025, enables the VA to efficiently procure the oncology medication Adstiladrin (nadofaragene firadenovec) to support the provision of healthcare...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Acorda Therapeutics, Inc. for the procurement of Inbrija and Ampyra. The contract has a potential value of $7.5 million and a period of performance through January 2024. The contract was awarded off the Pharmaceuticals and Drugs Federal Supply Schedule and provides a single award vehicle for ordering Inbrija, a treatment for off episodes related to Parkinson's disease, and Ampyra, a...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a specialty pharmaceutical company, a Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This multiple-award IDV contract has a ceiling value of $27,736,880 and a period of performance through April 2026. Under this FSS contract, Chiesi USA Inc. has received several delivery orders to supply pharmaceutical products, primarily deferiprone and luspatercept, to VA medical facilities and integrated...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79719D0160-36E79724A0023 | Catalyst Pharmaceuticals, Inc. | $5.5m | 7/26/24 | 7/25/26 | 6/11/25 | |
36F79719D0160-36E79719A0027 | Catalyst Pharmaceuticals, Inc. | $10.0m | 7/26/19 | 7/25/24 | 12/15/23 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 36F79719D0160-36C24524N0953 | Catalyst Pharmaceuticals, Inc. | $18.5k | 9/23/24 | 9/27/24 | 9/23/24 | |
Delivery Order 36F79719D0160-36C24520F0231 | Catalyst Pharmaceuticals, Inc. | $15.1k | 12/12/19 | 12/16/19 | 12/12/19 | |
Delivery Order 36F79719D0160-36C24519F0842 | Catalyst Pharmaceuticals, Inc. | $15.1k | 8/21/19 | 8/22/19 | 8/21/19 | |
Delivery Order 36F79719D0160-36C26023F0042 | Catalyst Pharmaceuticals, Inc. | $132.9k | 11/1/22 | 10/31/23 | 6/27/24 | |
Delivery Order 36F79719D0160-36C24719F0823 | Catalyst Pharmaceuticals, Inc. | $90.7k | 9/17/19 | 9/30/19 | 9/17/19 |